Just to put the timeline of the ZEN-3694 trials in context......

Resverlogix aside, and not counting trials that were withdrawn prior to enrollment or terminated, there have been very few BET inhibitor trials that have reached completion. According to ClinicalTrials.gov, there have been two MK-8628/OTX015 Phase 1 trials that have been completed (NCT01713582 and NCT02259114) and there has been one GSK525762 Phase 1 trial that has been completed (NCT02706535). All the others on the list are still ongoing (if not withdrawn or terminated).

Most of the ongoing trials started prior to the ZEN-3694 trials. Most are Phase 1 trials, however Gilead has a couple Phase 1/2 trials ongoing with GS-5829, Constellation has a Phase 2 trial not yet recruiting for CPI-0610, GSK has a couple of ongoing Phase 2 trials for GSK525762, Incyte has Phase 2 trials ongoing for both INCB054329 and INCB057643, and BMS has a Phase 1/2 trial ongoing for BMS-986158.

So although we have been anxiously waiting ZEN-3694 results......the results of a long list of other BET inhibitor trials are still pending as well. Hopefully we hear something in Q4 2017 for ZEN-3694 either in a couple weeks at BIO Investor or by December at the AGM.

Have a great weekend,

BearDownAZ